Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 79,050 shares at $67.50 ($5.3M) on 2026-05-07, disclosed to the SEC on 2026-05-11.
Scheduled sale ($5.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $67.49 | 11,217 | $757K | 14.2% |
| 2 | $67.50 | 11,217 | $757K | 14.2% |
| 3 | $68.38 | 8,333 | $570K | 10.7% |
| 4 | $68.38 | 8,334 | $570K | 10.7% |
| 5 | $69.09 | 449 | $31K | 0.6% |
| 6 | $69.09 | 450 |
| $31K |
| 0.6% |
| 7 | $66.65 | 13,973 | $931K | 17.5% |
| 8 | $66.65 | 13,974 | $931K | 17.5% |
| 9 | $67.35 | 5,076 | $342K | 6.4% |
| 10 | $67.35 | 5,077 | $342K | 6.4% |
| 11 | $68.35 | 950 | $65K | 1.2% |
| Total | $67.39 avg | 79,050 | $5.3M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-04-13 | $6.0M | — | Filing → |